ArticleClinical journal of the American Society of Nephrology : CJASN2010
Renal function and healthcare costs in patients with polycystic kidney disease.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.American journal of nephrology · 2017Trial
- Association between nephrolithiasis and kidney disease progression in patients with autosomal dominant polycystic kidney disease: a prospective cohort study.Clinical kidney journal · 2026Article
- Cost-Minimization Analysis of Tolvaptan Treatment for ADPKD in Southern Spain.Kidney international reports · 2025Article
- Caregiver Burden of Autosomal Dominant Polycystic Kidney Disease: A Qualitative Study.Kidney medicine · 2023Article
- A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.BMC nephrology · 2022Article
- The fertility willingness and acceptability of preimplantation genetic testing in Chinese patients with autosomal dominant polycystic kidney disease.BMC nephrology · 2020Article
- The relationship between liver cyst volume and QOL in Japanese ADPKD patients.Clinical and experimental nephrology · 2020Article
- The societal economic burden of autosomal dominant polycystic kidney disease in the United States.BMC health services research · 2020Article
- Renal Volume in ADPKD Patient Evaluation.International journal of nephrology · 2020Article
- Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.European journal of pediatrics · 2019Article
- Cerebral Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Comparison of Management Approaches.Neurosurgery · 2019Article
- Analysis of Nationwide Data to Determine the Incidence and Diagnosed Prevalence of Autosomal Dominant Polycystic Kidney Disease in the USA: 2013-2015.Kidney diseases (Basel, Switzerland) · 2019Article
- Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.International journal of medical sciences · 2019Article
- Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease.Canadian journal of kidney health and disease · 2018Article
- Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment.International journal of nephrology and renovascular disease · 2018Review
- Modeling Renal Disease "On the Fly".BioMed research international · 2018Review
- Incremental health care resource utilization and expenditures associated with autosomal-dominant polycystic kidney disease.ClinicoEconomics and outcomes research : CEOR · 2018Article
- Article
- Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.BMC health services research · 2017Observational
- Prevalence of autosomal dominant polycystic kidney disease in the European Union.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesCharacterizing relationships of kidney function to healthcare costs in polycystic kidney disease has applications for economic evaluations of standard and emerging therapies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The administrative records (2003 to 2006) of a private health insurer were examined to identify polycystic kidney disease patients (n = 1913) from ICD9 diagnosis codes on billing claims. The first available diagnostic claim was assumed as an index date, and baseline estimated GFR (eGFR) was computed using closest serum creatinine value. The associations of eGFR with annualized charges were modeled by nonlinear and linear regression.
resultsMedical, pharmacy, and total healthcare costs varied significantly by baseline kidney function, such that mean total annualized charges (unadjusted) were approximately 5-fold higher in patients with eGFR < 15 ml/min compared with those with eGFR >or= 90 ml/min. After adjustment for age and gender, total charges did not differ significantly among patients with eGFR > 30 ml/min, and but rose precipitously with eGFR < 30 ml/min. Each ml/min decline <30 ml/min predicted approximately $5435 higher adjusted annual charges. Results were similar after adjustment for baseline diabetes and cardiovascular disease as identified in claims, while significantly higher adjusted charges were detected with eGFR = 31 to 60 ml/min versus >or=90 ml/min in a subgroup free of diabetes and cardiovascular disease.
conclusionsHealthcare charges are associated with advanced renal dysfunction in polycystic kidney disease patients. Strategies that prevent loss of renal function below 30 ml/min have the potential to generate substantial reductions in medical charges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.